A Study of Neoadjuvant TCHpy（Pyrotinib ，Trastuzumab，Carboplatin and Paclitaxel）for ER+/HER2+ Breast Cancer

This study tests a combination drug regimen called TCHpy — pyrotinib, trastuzumab, carboplatin, and paclitaxel — as a pre-surgery treatment (neoadjuvant therapy) for women with HER2-positive breast cancer that also has estrogen receptor (ER) activity. **You may be eligible if...** - You are a female patient between 18 and 75 years old with no prior treatment for this cancer - Your breast cancer has been confirmed as HER2-positive by biopsy - Your tumor has an estrogen receptor (ER) positivity of at least 10% - Your tumor is at early or locally advanced stage with a primary tumor of at least 2 cm or lymph node involvement - Your blood counts, liver function, kidney function, and heart function meet the required minimums **You may NOT be eligible if...** - You have been previously treated for breast cancer - Your heart function (ejection fraction) is below the required threshold - Your organ function tests (blood, liver, kidney) are significantly abnormal Talk to your doctor to see if this trial is right for you.